Catheter ablation for atrial fibrillation with heart failure

New England Journal of Medicine

Volumn 378, Issue 5, 2018, Pages 417-427

  Marrouche, Nassir F ^a   Brachmann, Johannes ^b   Andresen, Dietrich ^c   Siebels, Jürgen ^e   Boersma, Lucas ^f   Jordaens, Luc ^j   Merkely, Béla ^k   Pokushalov, Evgeny ^l   Sanders, Prashanthan ^m   Proff, Jochen ^d   Schunkert, Heribert ^d   Christ, Hildegard ^g   Vogt, Jürgen ⁱ   Bänsch, Dietmar ^h  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b KLINIKUM COBURG   (Germany)

^c Kardiologie An Den Ev Elisabeth Kliniken   (Germany)

^d Biotronik   (Germany)

^e Klinik Rotes Kreuz   (Germany)

^f Klinikum Links der Weser   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h Inst Med Stat Info Epidemiol   (Germany)

ⁱ KMG Klinikum Gustrow   (Germany)

^j ST ANTONIUS HOSPITAL   (Netherlands)

^k ERASMUS MEDICAL CENTER   (Netherlands)

^l SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^m MESHALKIN NATIONAL MEDICAL RESEARCH CENTER   (Russian Federation)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR MORTALITY; CATHETER ABLATION; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEW YORK HEART ASSOCIATION CLASS; PAROXYSMAL ATRIAL FIBRILLATION; PERICARDIAL EFFUSION; PERSISTENT ATRIAL FIBRILLATION; PRIORITY JOURNAL; PULMONARY VEIN STENOSIS; RANDOMIZED CONTROLLED TRIAL; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART RATE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; STATISTICS AND NUMERICAL DATA; WALK TEST;

ANTIARRHYTHMIC AGENT;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; VENTRICULAR FUNCTION, LEFT; WALK TEST;

EID: 85041417343     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1707855     Document Type: Article

References (31)

1. Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 2016; 133: 484-92.
2. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 2009; 119: 2516-25.
3. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials: Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 32: 695-703.
4. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107: 2920-5.
5. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975.
6. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18: 1609-78.
7. Roy D, Talajic M, Nattel SN, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-77.
8. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293: 2634-40.
9. Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal AF (RAAFT-2): a randomized trial. JAMA 2014; 311: 692-700.
10. Cosedis Nielsen J, Mortensen LS, Hansen PS. Radiofrequency ablation as initial therapy in paroxysmal AF. N Engl J Med 2013; 368: 478-9.
11. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130: 2071-104.
12. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with AF). Eur Heart J 2006; 27: 1979-2030.
13. Khan MN, Jaïs P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008; 359: 1778-85.
14. MacDonald MR, Connelly DT, Hawkins NM, et al. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart 2011; 97: 740-7.
15. Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013; 61: 1894-903.
16. Chen MS, Marrouche NF, Khaykin Y, et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 2004; 43: 1004-9.
17. Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 2016; 133: 1637-44.
18. Nieuwlaat R, Eurlings LF, Cleland JG, et al. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 2009; 53: 1690-8.
19. Verma A, Kalman JM, Callans DJ. Treatment of patients with atrial fibrillation and heart failure with reduced ejection fraction. Circulation 2017; 135: 1547-63.
20. Marrouche NF, Brachmann J. Catheter Ablation versus Standard Conventional Treatment in Patients with Left Ventricular Dysfunction and Atrial Fibrillation (CASTLE-AF) - study design. Pacing Clin Electrophysiol 2009; 32: 987-94.
21. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112(12): e154-e235.
22. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of AF: developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS), and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS): endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 2012; 9(4): 632-696.e21.
23. Müller HH, Schäfer H. A general statistical principle for changing a design any time during the course of a trial. Stat Med 2004; 23: 2497-508.
24. Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol 2014; 7: 31-8.
25. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.
26. Torp-Pedersen C, Møller M, Bloch- Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999; 341: 857-65.
27. Doyle JF, Ho KM. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clin Proc 2009; 84: 234-42.
28. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter- defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-37.
29. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol 2003; 41: 1707-12.
30. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-83.
31. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933-40.